Hopes Gets High After Pfizer-BioNTech’s COVID-19 Vaccine Found To Be 90 Percent Effective

Hopes have risen after a vaccine candidate BNT162b2 developed by Pfizer together with BioNTech has shown to be 90 percent effective in preventing Covid-19 infections in ongoing Phase 3 trials, company officials told.

The company started its study on 43,538 participants out of these 38,955 have received a second dose of the vaccine candidate as of November 8. However, the finding was the result of the first independent analysis of any coronavirus vaccine candidate currently in phase 3 trials.

Also, the study showed that 94 participants who got the two-dose vaccine were protected against the virus, 28 days after their first shot.

No more details were disclosed by the company expect that the initial protection rate might change by the time the study ends and even revealing such early data is highly unusual.

According to the WHO standards, no vaccine is 100 percent effective while as per The US Food and Drug Administration’s criteria, a Covid vaccine is approved if it shows at least 50 percent efficacy in phase 3 trials.

Pfizer also claimed that the company is gathering two months of safety data following the final dose, which is a requirement of the FDA, to qualify for EUA, which it expects by the third week in November.

Meanwhile, hopes have been high after the news flashed on the media. The success in this could mean the end to the coronavirus time.